Tradestie Institutional Equity Comparison Engine

VIVS vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
VIVS N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -10117.0% vs -485.4% ยท YoY -51.4% vs +408.6%
Momentum & Technical Winner SRZN
1Y -87.0% vs +136.8% ยท 52W Pos 5% vs 72%
Options & Structure Winner SRZN
BREAKDOWN (N/A IV) vs CONSOLIDATION (5th %ile IV)
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$30.67
-3.37% 1D
Market Cap $665.1M
1M Return +21.13%
1Y Return +136.83%
Forward P/E N/M
Unified AI Score
42.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 64.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VIVS -86.99% SRZN +136.83% Spread: +223.82 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VIVS Revenue SRZN Revenue VIVS Op. Margin SRZN Op. Margin Margin Edge
FY2018 $0M N/A -766.3% N/A VIVS
FY2019 $0M N/A -882.4% N/A VIVS
FY2020 $0M N/A -977.9% N/A VIVS
FY2022 $0M $10M -765.3% -354.7% SRZN
FY2023 $0M N/A -4792.2% N/A VIVS
FY2024 $0M $10M -13840.4% -239.7% SRZN
FY2025 $0M $0M -8761.1% -1210.6% SRZN
FY2026 $0M N/A -8768.7% N/A VIVS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VIVS (0) vs SRZN (7)
Institutional Metric VIVS SRZN Criterion Row Winner
Market Capitalization Scale $2.4M $665.1M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -51.4% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability -10117.0% -485.4% Higher Margin SRZN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -343.1% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 5% ($0โ€“$3) 72% ($13โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 0.83ฮฒ ยท 480% Vol 1.25ฮฒ ยท 70% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 42.8 / 100 (HOLD) Higher Composite SRZN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VIVS vs SRZN Buy Guide
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
40d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VIVS nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.